395 related articles for article (PubMed ID: 2877575)
21. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
[TBL] [Abstract][Full Text] [Related]
22. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Ohsawa T; Hirata W; Higichi S
Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
[TBL] [Abstract][Full Text] [Related]
23. The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration.
Decktor D; Houle JM; Pierce CH
Am J Ther; 1998 Mar; 5(2):97-100. PubMed ID: 10099044
[TBL] [Abstract][Full Text] [Related]
24. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
[TBL] [Abstract][Full Text] [Related]
25. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome.
Bardram L; Stadil F
Scand J Gastroenterol Suppl; 1989; 166():95-100; discussion 111-3. PubMed ID: 2574912
[TBL] [Abstract][Full Text] [Related]
26. What are the differences between the H2-receptor antagonists?
Schunack W
Aliment Pharmacol Ther; 1987; 1 Suppl 1():493S-503S. PubMed ID: 2908767
[TBL] [Abstract][Full Text] [Related]
27. Failure of histamine H2-receptor antagonist therapy in Zollinger-Ellison syndrome.
Stabile BE; Ippoliti AF; Walsh JH; Passaro E
Am J Surg; 1983 Jan; 145(1):17-23. PubMed ID: 6129812
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. A prospective study.
Richardson CT; Peters MN; Feldman M; McClelland RN; Walsh JH; Cooper KA; Willeford G; Dickerman RM; Fordtran JS
Gastroenterology; 1985 Aug; 89(2):357-67. PubMed ID: 2861140
[TBL] [Abstract][Full Text] [Related]
29. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
30. Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Grimley CE; West JM; Loft DE; Cottrell J; Mann SG; Stauffer L; Nwokolo CU
Aliment Pharmacol Ther; 1996 Oct; 10(5):743-7. PubMed ID: 8899082
[TBL] [Abstract][Full Text] [Related]
31. Frequent non-response to histamine H2-receptor antagonists in cirrhotics.
Walker S; Krishna DR; Klotz U; Bode JC
Gut; 1989 Aug; 30(8):1105-9. PubMed ID: 2570008
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology of H2-receptor antagonists: an overview.
Schunack W
J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery.
Lamothe PH; Rao E; Serra AJ; Castellano J; Woronick CL; McNicholas KW; Lemole GM
Gastroenterology; 1991 Jun; 100(6):1515-20. PubMed ID: 2019357
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Saha N; Sachdev A; Bhasin DK; Sankaranahyanan A; Khosla PP; Singh K; Sharma PL
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
[TBL] [Abstract][Full Text] [Related]
36. Ranitidine: a new H2-receptor antagonist.
Berner BD; Conner CS; Sawyer DR; Siepler JK
Clin Pharm; 1982; 1(6):499-509. PubMed ID: 6309467
[TBL] [Abstract][Full Text] [Related]
37. Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton MI; Sercombe J; Pounder RE
Aliment Pharmacol Ther; 2001 Oct; 15(10):1579-83. PubMed ID: 11563997
[TBL] [Abstract][Full Text] [Related]
38. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.
Savarino V; Mela GS; Scalabrini P; Di Timoteo E; Magnolia MR; Celle G
Digestion; 1987; 37(2):103-9. PubMed ID: 3305114
[TBL] [Abstract][Full Text] [Related]
39. Famotidine in the USA: a review of efficacy studies.
Gitnick G
J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
[TBL] [Abstract][Full Text] [Related]
40. Marked basal gastric acid hypersecretion and peptic ulcer disease: medical management with a combination H2-histamine receptor antagonist and anticholinergic.
Hyman PE; Hassall E
J Pediatr Gastroenterol Nutr; 1988; 7(1):57-63. PubMed ID: 2891809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
